Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

860 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-20

Study Completion Date

2022-10-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

NCT06727734

Contraception

NOT_YET_RECRUITING PHASE3

Effect of Piroxicam on Ovulation

NCT01320709

Contraception, Postcoital

COMPLETED PHASE2

Levonorgestrel Intrauterine System For Emergency Contraception

NCT01539720

Pregnancy, Unplanned Pregnancy; Accident

COMPLETED NA

Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG

NCT01286948

Female Contraception

COMPLETED PHASE1

Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

NCT02021097

Oral Contraceptive

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: To compare the percentage of pregnancies prevented by LNG co-administered with piroxicam or placebo for oral emergency contraception (EC) by a randomised controlled trial.

Hypothesis to be tested: LNG plus piroxicam has higher percentage of pregnancies prevented compared with LNG plus placebo for oral emergency contraception.

Design and subjects: This will be a prospective, randomised placebo-controlled clinical trial. Women attending the Family Planning Association of Hong Kong for oral EC within 72 hours of unprotected sexual intercourse will be recruited.

Study instruments: Prospective follow-up of subjects in the clinic for the primary and secondary outcomes.

Interventions: Eligible subjects will be randomised to receive one of the two treatment regimens, i.e. Group A: a single dose of LNG 1.5 mg and piroxicam 40 mg, or Group B: a single dose of LNG 1.5mg and placebo under direct supervision.

Main outcome measures: Percentage of pregnancies prevented (PPP) is the primary outcome measure. Secondary outcome measures include failure rate, rate of occurrence of side effects and pattern of the menstruation following EC.

Data analysis:The percentage of pregnancies prevented, failure rate and rate of occurrence of side effects will be compared between groups using Fisher-Exact test. Continuous variables regarding menstrual pattern between the two groups will be compared by Mann-Whitney U test.

Expected results: LNG plus piroxicam has a higher PPP compared to LNG plus placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emergency Contraception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Piroxicam

Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose

Group Type ACTIVE_COMPARATOR

Piroxicam 40 mg

Intervention Type DRUG

Additional co-treatment

Levonorgestrel 1.5mg

Intervention Type DRUG

Standard treatment

Placebo

Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose

Group Type PLACEBO_COMPARATOR

Levonorgestrel 1.5mg

Intervention Type DRUG

Standard treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Piroxicam 40 mg

Additional co-treatment

Intervention Type DRUG

Levonorgestrel 1.5mg

Standard treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy women aged 18 years or above;
* requesting emergency contraception within 72 h of a single act of unprotected intercourse in the current menstrual cycle;
* having menstrual cycles between 24 and 42 days
* willing to abstain from further acts of unprotected intercourse and;
* available for follow-up over the next 6 weeks.

Exclusion Criteria

* post-abortion or postpartum and period have not yet returned,
* being on prescription drugs currently
* having unprotected intercourse in this cycle more than 72 hours or more than once before attending the clinic,
* being found pregnant at the time of presentation,
* breastfeeding,
* having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ,
* uncertain about the date of the last menstrual period,
* having used hormonal contraceptive (including EC pill) or NSAID in the current or past one cycle,
* having history of asthma, urticarial or other allergic reactions to piroxicam, aspirin or other NSAIDs,
* having history of ischaemic heart disease in the past one year
* having history of pelvic ulcer disease and/or gastrointestinal bleeding

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes